Roche 10 Medicine - Search News

Roche, Zealand and weight loss

Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.

Quartz on MSN · 1d

Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.

AOL · 2d

Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%

Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would

Investor's Business Daily on MSN · 2d

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Seeking Alpha · 2d

Roche-Zealand deal is the latest to boost obesity space

Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts weight loss drug stocks. Read more here.

STAT2d

Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

the current widely prescribed type of medicine aimed at obesity and diabetes. Roche has been making the case that the obesity market is large enough for it to enter the field, if a bit later than ...

5monon MSN

The 10 Best La Roche-Posay Products for Every Skin Concern, Tested by Editors

Skin care aficionados everywhere are making space for a dermatologist-backed, budget-friendly brand in their medicine ...

Fierce Pharma11d

Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic stroke

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

pharmaphorum9d

FDA starts review of Roche's Gazyva in lupus nephritis

The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results